214 related articles for article (PubMed ID: 29925907)
1. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O; Blom S; Dufva O; Turkki R; Chheda H; Ribeiro A; Kovanen P; Aittokallio T; Koskenvesa P; Kallioniemi O; Porkka K; Pellinen T; Mustjoki S
Leukemia; 2018 Jul; 32(7):1643-1656. PubMed ID: 29925907
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
[TBL] [Abstract][Full Text] [Related]
3. Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL.
Hohtari H; Brück O; Blom S; Turkki R; Sinisalo M; Kovanen PE; Kallioniemi O; Pellinen T; Porkka K; Mustjoki S
Leukemia; 2019 Jul; 33(7):1570-1582. PubMed ID: 30635636
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
[TBL] [Abstract][Full Text] [Related]
5. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Rohon P; Porkka K; Mustjoki S
Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
[TBL] [Abstract][Full Text] [Related]
6. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Lanza F; Bi S; Castoldi G; Goldman JM
Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment.
Yao D; Lai J; Lu Y; Zhong J; Zha X; Huang X; Liu L; Zeng X; Chen S; Weng J; Du X; Li Y; Xu L
Front Immunol; 2023; 14():1078118. PubMed ID: 36742315
[TBL] [Abstract][Full Text] [Related]
8. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
9. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
[TBL] [Abstract][Full Text] [Related]
10. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
[TBL] [Abstract][Full Text] [Related]
11. T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.
Bhatia R; McGlave PB
Leukemia; 1995 Jun; 9(6):1006-12. PubMed ID: 7596165
[TBL] [Abstract][Full Text] [Related]
12. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
13. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
[TBL] [Abstract][Full Text] [Related]
14. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
Front Immunol; 2019; 10():2493. PubMed ID: 31695700
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Hus I; Tabarkiewicz J; Lewandowska M; Wasiak M; Wdowiak P; Kusz M; Legieć M; Dmoszyńska A; Roliński J
Folia Histochem Cytobiol; 2011; 49(1):153-60. PubMed ID: 21526503
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow.
Park M; Park CJ; Cho YW; Jang S; Lee JH; Lee JH; Lee KH; Lee YH
Exp Hematol; 2017 Jan; 45():56-63. PubMed ID: 27693387
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
18. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.
Sopper S; Mustjoki S; White D; Hughes T; Valent P; Burchert A; Gjertsen BT; Gastl G; Baldauf M; Trajanoski Z; Giles F; Hochhaus A; Ernst T; Schenk T; Janssen JJ; Ossenkoppele GJ; Porkka K; Wolf D
J Clin Oncol; 2017 Jan; 35(2):175-184. PubMed ID: 28056193
[TBL] [Abstract][Full Text] [Related]
19. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients.
Feuerer M; Rocha M; Bai L; Umansky V; Solomayer EF; Bastert G; Diel IJ; Schirrmacher V
Int J Cancer; 2001 Apr; 92(1):96-105. PubMed ID: 11279612
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]